查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1621310

肉瘤药物市场：按适应症、按药物、按销售管道、按最终用户划分 - 全球预测 2025-2030

Sarcoma Drugs Market by Indication (Angiosarcoma, Chondrosarcoma, Dermatofibrosarcoma Protuberans), Drugs (Chemotherapy Drugs, Immunotherapy Drugs, Targeted Drug Therapy), Sales Channel, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

肉瘤治疗市场2023年估值为15.4亿美元，预计到2024年将达到16.6亿美元，复合年增长率为8.10%，到2030年预计将达到26.6亿美元。

肉瘤治疗药物市场范围和定义涵盖旨在治疗肉瘤的药物治疗的开发、生产和分销，肉瘤是一种影响骨骼和软组织的罕见且异质性的间质来源肿瘤。迫切需要肉瘤药物来改善受这一多样化群体影响的患者的生存和结果，该群体有 50 多种亚型，并且通常具有不同的遗传观察。这些药物的应用包括手术、化疗和免疫疗法中的新辅助和辅助治疗，并且越来越多地采用创新方法和标靶治疗。最终用途范围主要包括医院、癌症治疗中心和向患者提供这些治疗的专科诊所。

主要市场统计
基准年[2023] 15.4亿美元
预测年份 [2024] 16.6亿美元
预测年份 [2030] 26.6亿美元
复合年增长率（%） 8.10%

根据市场洞察，关键的成长要素包括诊断技术的进步、研发投资的增加以及对肉瘤病理学了解的加深，从而促进新药的开发。此外，与孤儿药指定相关的监管优势，以及医疗保健支出和宣传宣传活动，带来了巨大的商机。公司应该利用精准医疗创新的潜在机会，利用基因和分子分析进行标靶治疗。然而，市场受到高昂的治疗开发成本、严格的监管核准、有限的患者群体（降低了经济吸引力）以及肉瘤类型的异质性（使临床试验和药物疗效复杂化）的限制。

儘管有这些挑战，创新和研究潜力最大的领域包括免疫肿瘤学、生物相似药开发和个人化医疗方法。共用研究和开发倡议以及强调促进药物监管的伙伴关係也可能提供策略优势。此外，给药机制和组合治疗策略的创新有可能增强患者的反应和治疗结果。市场竞争仍然激烈，各公司正专注于併购、联盟和伙伴关係关係，以加强其产品组合併满足肉瘤治疗方面未满足的需求。总之，相关人员必须克服复杂的法规，投资于有针对性的研究，并采取策略联盟以实现市场的可持续成长。

市场动态：揭示快速发展的肉瘤药物市场的关键市场洞察

肉瘤药物市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 肉瘤发生率不断增加，需要有效的治疗方案
    • 政府鼓励肉瘤治疗的努力
    • 政府对改良肉瘤药物的有利核准
  • 市场限制因素
    • 肉瘤的报销限制
  • 市场机会
    • 持续研究和开发先进和新型肉瘤疗法
    • 改善肉瘤的标靶治疗和免疫治疗方法
  • 市场挑战
    • 肉瘤的抗药性问题

波特五力：驾驭肉瘤药物市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解肉瘤药物市场的外部影响

外部宏观环境因素在塑造肉瘤治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解肉瘤治疗药物市场的竞争状况

对肉瘤治疗药物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位基质肉瘤治疗市场供应商的绩效评估

FPNV定位矩阵是评估肉瘤治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製肉瘤药物市场的成功之路

对于希望加强在全球市场的影响力的公司来说，对肉瘤药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开发：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、未开发地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 肉瘤发生率增加以及有效治疗方法的需要
      • 政府鼓励肉瘤治疗的努力
      • 政府对改良肉瘤药物的有利核准
    • 抑制因素
      • 肉瘤的补偿有限
    • 机会
      • 持续研究和开发先进的新肉瘤治疗方法
      • 改善肉瘤的标靶治疗和免疫治疗方法
    • 任务
      • 与肉瘤抗药性相关的问题
  • 市场区隔分析
    • 适应症：平滑肌肉瘤发生率高，开发新药值得期待。
    • 製药：采用标靶肉瘤疗法，根据个别基因突变进行更客製化的治疗
    • 销售管道：由于处方药宅配服务的便利性，线上销售管道越来越受到青睐。
    • 最终使用者：为医院和诊所不同类型和阶段的肉瘤患者提供多种药物选择
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章肉瘤药物市场（按适应症）

  • 血管肉瘤
  • 软骨肉瘤
  • 隆突性皮肤纤维肉瘤
  • 上皮样肉瘤
  • 卡波西氏肉瘤
  • 平滑肌肉瘤
  • 脂肪肉瘤
  • 骨癌
  • 软组织肉瘤

第七章肉瘤药物治疗市场

  • 化疗药物
    • Cisplatin
    • 多西紫杉醇
    • 阿霉素
    • Etoposide
    • Gemcitabine
    • 异环磷酰胺
    • 紫杉醇
    • 曲贝替定
    • 长春新碱
  • 免疫治疗药物
    • Atezolizumab
    • Pembrolizumab
  • 标靶药物治疗
    • 恩曲替尼
    • Pazopanib
    • Sorafenib
    • Sunitinib
    • Tazemetostat

第八章肉瘤药物市场：按销售管道

  • 离线
    • 医院药房
    • 零售药房
  • 在线的

第九章肉瘤药物市场：依最终使用者分类

  • 癌症研究中心
  • 居家护理
  • 医院/诊所

第10章美洲肉瘤药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太肉瘤药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲肉瘤药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 住友製药肿瘤学获得治疗伊文氏肉瘤的孤儿药资格
    • FDA核准Atezolizumab用于治疗儿科患者的肺泡软组织肉瘤
    • 美国FDA 授予 Avacta 软组织肉瘤治疗孤儿药资格
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • AbbVie Inc.
  • AgonOx
  • Amneal Pharmaceuticals LLC
  • Aurobindo Pharma Limited
  • Avacta Life Sciences Limited
  • Baxter International Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Fresenius SE & Co. KGaA
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Ipsen Pharma
  • Johnson & Johnson Services, Inc.
  • Karyopharm Therapeutics Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceutical Industries Limited
  • TRACON Pharmaceuticals, Inc.
  • Viatris Inc.
Product Code: MRR-C002B1C996FA

The Sarcoma Drugs Market was valued at USD 1.54 billion in 2023, expected to reach USD 1.66 billion in 2024, and is projected to grow at a CAGR of 8.10%, to USD 2.66 billion by 2030.

The scope and definition of the sarcoma drugs market encompass the development, production, and distribution of pharmaceutical treatments aimed at tackling sarcomas, which are rare and heterogeneous tumors of mesenchymal origin affecting both bone and soft tissues. The necessity of sarcoma drugs arises from the pressing need to improve survival rates and treatment outcomes for patients suffering from this diverse group of over 50 subtypes, often characterized by distinct genetic findings. Application of these drugs includes neoadjuvant and adjuvant therapies in surgery, chemotherapy, and immunotherapy, where innovative approaches and targeted therapies are increasingly adopted. The end-use scope primarily involves hospitals, cancer treatment centers, and specialty clinics, which administer these treatments to patients.

KEY MARKET STATISTICS
Base Year [2023] USD 1.54 billion
Estimated Year [2024] USD 1.66 billion
Forecast Year [2030] USD 2.66 billion
CAGR (%) 8.10%

Market insights reveal that key growth factors include advancements in diagnostic technologies, increased R&D investment, and enhanced understanding of sarcoma pathogenesis leading to novel drug developments. Moreover, regulatory incentives for orphan drug designation foster significant opportunities, along with rising healthcare expenditure and awareness campaigns. Companies should capitalize on the innovation of precision medicine, exploiting genetic and molecular profiling for targeted therapies as a potential opportunity. However, the market faces limitations such as high costs of therapy development, stringent regulatory approvals, limited patient population leading to reduced financial allure, and heterogeneity of sarcoma types, which complicates clinical trials and drug efficacies.

Despite these challenges, the best potential areas for innovation and research include immuno-oncology, development of biosimilars, and personalized medicine approaches. Emphasis on partnerships for shared R&D initiatives and accelerated regulatory pathways may also provide strategic advantages. Furthermore, innovation in delivery mechanisms and combinatorial treatment strategies can enhance patient response and outcomes. The nature of the market remains highly competitive, with companies focusing on mergers and acquisitions, collaborations, and partnerships to strengthen their portfolios and meet the unmet needs in sarcoma treatment. Conclusively, stakeholders must navigate regulatory complexities, invest in targeted research, and adopt strategic collaborations for sustained market growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Sarcoma Drugs Market

The Sarcoma Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incidence of sarcoma and the need for effective treatment options
    • Government initiatives encouraging the treatment of sarcoma
    • Favorable government approvals for improved sarcoma drugs
  • Market Restraints
    • Limited reimbursements available for sarcoma
  • Market Opportunities
    • Ongoing research and development for advanced and new sarcoma drugs
    • Improvements in targeted and immunotherapy approaches for sarcoma
  • Market Challenges
    • Issues associated with drug resistance in sarcomas

Porter's Five Forces: A Strategic Tool for Navigating the Sarcoma Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Sarcoma Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Sarcoma Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Sarcoma Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Sarcoma Drugs Market

A detailed market share analysis in the Sarcoma Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Sarcoma Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Sarcoma Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Sarcoma Drugs Market

A strategic analysis of the Sarcoma Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Sarcoma Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., AgonOx, Amneal Pharmaceuticals LLC, Aurobindo Pharma Limited, Avacta Life Sciences Limited, Baxter International Inc., Bayer AG, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Fresenius SE & Co. KGaA, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Ipsen Pharma, Johnson & Johnson Services, Inc., Karyopharm Therapeutics Inc., Lupin Limited, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sumitomo Pharma Co., Ltd., Sun Pharmaceutical Industries Limited, TRACON Pharmaceuticals, Inc., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Sarcoma Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Indication, market is studied across Angiosarcoma, Chondrosarcoma, Dermatofibrosarcoma Protuberans, Epithelioid Sarcoma, Kaposi's Sarcoma, Leiomyosarcoma, Liposarcoma, Osteosarcoma, and Soft Tissue Sarcoma.
  • Based on Drugs, market is studied across Chemotherapy Drugs, Immunotherapy Drugs, and Targeted Drug Therapy. The Chemotherapy Drugs is further studied across Cisplatin, Docetaxel, Doxorubicin, Etoposide, Gemcitabine, Ifosfamide, Paclitaxel, Trabectedin, and Vincristine. The Immunotherapy Drugs is further studied across Atezolizumab and Pembrolizumab. The Targeted Drug Therapy is further studied across Entrectinib, Pazopanib, Sorafenib, Sunitinib, and Tazemetostat.
  • Based on Sales Channel, market is studied across Offline and Online. The Offline is further studied across Hospitals Pharmacies and Retail Pharmacies.
  • Based on End-User, market is studied across Cancer Research Center, Homecare, and Hospital & clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidence of sarcoma and the need for effective treatment options
      • 5.1.1.2. Government initiatives encouraging the treatment of sarcoma
      • 5.1.1.3. Favorable government approvals for improved sarcoma drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Limited reimbursements available for sarcoma
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and development for advanced and new sarcoma drugs
      • 5.1.3.2. Improvements in targeted and immunotherapy approaches for sarcoma
    • 5.1.4. Challenges
      • 5.1.4.1. Issues associated with drug resistance in sarcomas
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Indication: High incidence rates of leiomyosarcoma encouraging new drug development
    • 5.2.2. Drugs: Adoption of targeted sarcoma drugs for more tailored treatment based on individual genetic mutations
    • 5.2.3. Sales Channel: Emerging preference for online sales channel driven by their convenience for home delivery services of prescription medications
    • 5.2.4. End-User: Wide range of drug options to cater to various types and stages of sarcoma patients in hospitals & clinics
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Sarcoma Drugs Market, by Indication

  • 6.1. Introduction
  • 6.2. Angiosarcoma
  • 6.3. Chondrosarcoma
  • 6.4. Dermatofibrosarcoma Protuberans
  • 6.5. Epithelioid Sarcoma
  • 6.6. Kaposi's Sarcoma
  • 6.7. Leiomyosarcoma
  • 6.8. Liposarcoma
  • 6.9. Osteosarcoma
  • 6.10. Soft Tissue Sarcoma

7. Sarcoma Drugs Market, by Drugs

  • 7.1. Introduction
  • 7.2. Chemotherapy Drugs
    • 7.2.1. Cisplatin
    • 7.2.2. Docetaxel
    • 7.2.3. Doxorubicin
    • 7.2.4. Etoposide
    • 7.2.5. Gemcitabine
    • 7.2.6. Ifosfamide
    • 7.2.7. Paclitaxel
    • 7.2.8. Trabectedin
    • 7.2.9. Vincristine
  • 7.3. Immunotherapy Drugs
    • 7.3.1. Atezolizumab
    • 7.3.2. Pembrolizumab
  • 7.4. Targeted Drug Therapy
    • 7.4.1. Entrectinib
    • 7.4.2. Pazopanib
    • 7.4.3. Sorafenib
    • 7.4.4. Sunitinib
    • 7.4.5. Tazemetostat

8. Sarcoma Drugs Market, by Sales Channel

  • 8.1. Introduction
  • 8.2. Offline
    • 8.2.1. Hospitals Pharmacies
    • 8.2.2. Retail Pharmacies
  • 8.3. Online

9. Sarcoma Drugs Market, by End-User

  • 9.1. Introduction
  • 9.2. Cancer Research Center
  • 9.3. Homecare
  • 9.4. Hospital & clinics

10. Americas Sarcoma Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Sarcoma Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Sarcoma Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Sumitomo Pharma Oncology receives orphan drug designation for Ewing sarcoma treatment
    • 13.3.2. FDA approves atezolizumab for alveolar soft part sarcoma in pediatric patients
    • 13.3.3. US FDA grants Orphan Drug status to Avacta's drug for soft tissue sarcoma
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. AgonOx
  • 4. Amneal Pharmaceuticals LLC
  • 5. Aurobindo Pharma Limited
  • 6. Avacta Life Sciences Limited
  • 7. Baxter International Inc.
  • 8. Bayer AG
  • 9. Bristol-Myers Squibb Company
  • 10. Daiichi Sankyo Company, Limited
  • 11. Eisai Co., Ltd.
  • 12. Eli Lilly and Company
  • 13. F. Hoffmann-La Roche Ltd.
  • 14. Fresenius SE & Co. KGaA
  • 15. GlaxoSmithKline PLC
  • 16. Hikma Pharmaceuticals PLC
  • 17. Ipsen Pharma
  • 18. Johnson & Johnson Services, Inc.
  • 19. Karyopharm Therapeutics Inc.
  • 20. Lupin Limited
  • 21. Merck & Co., Inc.
  • 22. Novartis AG
  • 23. Pfizer Inc.
  • 24. Sumitomo Pharma Co., Ltd.
  • 25. Sun Pharmaceutical Industries Limited
  • 26. TRACON Pharmaceuticals, Inc.
  • 27. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. SARCOMA DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. SARCOMA DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SARCOMA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SARCOMA DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL SARCOMA DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL SARCOMA DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. SARCOMA DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. SARCOMA DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SARCOMA DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SARCOMA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SARCOMA DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. SARCOMA DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANGIOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHONDROSARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DERMATOFIBROSARCOMA PROTUBERANS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL SARCOMA DRUGS MARKET SIZE, BY EPITHELIOID SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL SARCOMA DRUGS MARKET SIZE, BY KAPOSI'S SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LEIOMYOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LIPOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL SARCOMA DRUGS MARKET SIZE, BY OSTEOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CISPLATIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DOCETAXEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DOXORUBICIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ETOPOSIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL SARCOMA DRUGS MARKET SIZE, BY GEMCITABINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IFOSFAMIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PACLITAXEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TRABECTEDIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL SARCOMA DRUGS MARKET SIZE, BY VINCRISTINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ENTRECTINIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PAZOPANIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SORAFENIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SUNITINIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TAZEMETOSTAT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL SARCOMA DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL SARCOMA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CANCER RESEARCH CENTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOSPITAL & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 114. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 116. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. CHINA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 124. CHINA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. INDIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. INDIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 132. INDIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. INDONESIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. INDONESIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. JAPAN SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. JAPAN SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 143. JAPAN SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 144. JAPAN SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 146. JAPAN SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 151. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 152. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 153. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 154. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 158. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 160. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 162. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 164. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 166. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 167. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 168. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 169. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 170. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 172. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 175. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 176. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 177. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 178. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 180. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. TAIWAN SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. TAIWAN SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 183. TAIWAN SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 184. TAIWAN SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 185. TAIWAN SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 186. TAIWAN SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. TAIWAN SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 188. TAIWAN SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. THAILAND SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 190. THAILAND SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 191. THAILAND SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 192. THAILAND SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 193. THAILAND SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 194. THAILAND SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 195. THAILAND SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 196. THAILAND SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 197. VIETNAM SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 198. VIETNAM SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 199. VIETNAM SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 200. VIETNAM SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 201. VIETNAM SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 202. VIETNAM SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 203. VIETNAM SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 204. VIETNAM SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 214. DENMARK SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 215. DENMARK SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 216. DENMARK SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 217. DENMARK SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 218. DENMARK SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 219. DENMARK SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 220. DENMARK SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 221. DENMARK SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 222. EGYPT SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 223. EGYPT SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 224. EGYPT SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 225. EGYPT SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 226. EGYPT SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 227. EGYPT SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 228. EGYPT SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 229. EGYPT SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 230. FINLAND SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 231. FINLAND SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 232. FINLAND SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 233. FINLAND SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 234. FINLAND SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 235. FINLAND SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 236. FINLAND SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 237. FINLAND SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 238. FRANCE SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 239. FRANCE SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 240. FRANCE SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 241. FRANCE SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 242. FRANCE SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 243. FRANCE SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 244. FRANCE SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 245. FRANCE SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 246. GERMANY SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 247. GERMANY SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 248. GERMANY SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 249. GERMANY SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 250. GERMANY SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 251. GERMANY SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 252. GERMANY SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 253. GERMANY SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 254. ISRAEL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 255. ISRAEL SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 256. ISRAEL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 257. ISRAEL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 258. ISRAEL SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 259. ISRAEL SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 260. ISRAEL SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 261. ISRAEL SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 262. ITALY SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 263. ITALY SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 264. ITALY SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 265. ITALY SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 266. ITALY SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 267. ITALY SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 268. ITALY SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 269. ITALY SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 270. NETHERLANDS SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 271. NETHERLANDS SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 272. NETHERLANDS SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 273. NETHERLANDS SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 274. NETHERLANDS SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 275. NETHERLANDS SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 276. NETHERLANDS SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 277. NETHERLANDS SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 278. NIGERIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 279. NIGERIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 280. NIGERIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 281. NIGERIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 282. NIGERIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 283. NIGERIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 284. NIGERIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 285. NIGERIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 286. NORWAY SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 287. NORWAY SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 288. NORWAY SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 289. NORWAY SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 290. NORWAY SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 291. NORWAY SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 292. NORWAY SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 293. NORWAY SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 294. POLAND SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 295. POLAND SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 296. POLAND SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 297. POLAND SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 298. POLAND SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 299. POLAND SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 300. POLAND SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 301. POLAND SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 302. QATAR SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 303. QATAR SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 304. QATAR SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 305. QATAR SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 306. QATAR SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 307. QATAR SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 308. QATAR SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 309. QATAR SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 310. RUSSIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 311. RUSSIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 312. RUSSIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 313. RUSSIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 314. RUSSIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 315. RUSSIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 316. RUSSIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 317. RUSSIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 318. SAUDI ARABIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 319. SAUDI ARABIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 320. SAUDI ARABIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 321. SAUDI ARABIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 322. SAUDI ARABIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 323. SAUDI ARABIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 324. SAUDI ARABIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 325. SAUDI ARABIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 326. SOUTH AFRICA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 327. SOUTH AFRICA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 328. SOUTH AFRICA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 329. SOUTH AFRICA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 330. SOUTH AFRICA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 331. SOUTH AFRICA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 332. SOUTH AFRICA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 333. SOUTH AFRICA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 334. SPAIN SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 335. SPAIN SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 336. SPAIN SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 337. SPAIN SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 338. SPAIN SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 339. SPAIN SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 340. SPAIN SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 341. SPAIN SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 342. SWEDEN SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 343. SWEDEN SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 344. SWEDEN SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 345. SWEDEN SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 346. SWEDEN SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 347. SWEDEN SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 348. SWEDEN SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 349. SWEDEN SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 350. SWITZERLAND SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 351. SWITZERLAND SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 352. SWITZERLAND SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 353. SWITZERLAND SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 354. SWITZERLAND SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 355. SWITZERLAND SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 356. SWITZERLAND SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 357. SWITZERLAND SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 358. TURKEY SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 359. TURKEY SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 360. TURKEY SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 361. TURKEY SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 362. TURKEY SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 363. TURKEY SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 364. TURKEY SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 365. TURKEY SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 366. UNITED ARAB EMIRATES SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 367. UNITED ARAB EMIRATES SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 368. UNITED ARAB EMIRATES SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)

TABL